國藥(01099.HK)附屬中科器遭美國實施出口限制措施
國藥(01099.HK)公布,美國商務部工業與安全局決定將77個實體列入「實體清單」。公司注意到相關實體中包括公司附屬公司中科器。根據該決定,向中科器出口、再出口及境內轉讓受到美國出口管制條例規管的物項,須事先取得美國商務部工業與安全局的許可。
公司表示,中科器主要從事實驗室器材、非醫療設備的採購銷售業務。根據去年度按照中國會計準則編製的財務數據,中科器經審計的營業收入約佔公司經審計的合併口徑營業收入的0.7%,中科器經審計的稅前利潤約佔公司經審計的合併口徑稅前利潤的3.9%。
公司正就該決定對業務和經營的潛在影響進行綜合評估。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.